NCT00861705 · OUTCOME

Overall Survival

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery · Source last updated 2026-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: up to 10 years

What was measured

Number of Participants who Died Due to Any Cause

Analysis population: All treated patients

Groups in this outcome

Arm 1 (Pac --> ddAC)

Patients receive paclitaxel (pac) IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19. doxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV

Arm 2 (Pac + Bev --> ddAC + Bev)

Patients receive pac and ddAC as in arm 1. Patients also receive bevacizumab (bev) IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17. doxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV bevacizumab: Given IV

Arm 3 (Pac + Carboplatin --> ddAC)

Patients receive pac and ddAC as in arm 1. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10. doxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV carboplatin: Given IV

Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev)

Patients receive pac and ddAC as in arm 1, bev as in arm 2, and carboplatin as in arm 3. doxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV bevacizumab: Given IV carboplatin: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm 1 (Pac --> ddAC)	107
Arm 2 (Pac + Bev --> ddAC + Bev)	110
Arm 3 (Pac + Carboplatin --> ddAC)	112
Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev)	112

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Arm 1 (Pac --> ddAC)	22	Not reported	Not reported	Not reported	Not reported
Arm 2 (Pac + Bev --> ddAC + Bev)	26	Not reported	Not reported	Not reported	Not reported
Arm 3 (Pac + Carboplatin --> ddAC)	30	Not reported	Not reported	Not reported	Not reported
Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev)	24	Not reported	Not reported	Not reported	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
0.67
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
2.10
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
param Type
Cox Proportional Hazard
param Value
1.19
ci Lower Limit
0.82
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
2.47
group Ids
OG000
OG002
non Inferiority Type
SUPERIORITY
param Type
Cox Proportional Hazard
param Value
1.43
ci Lower Limit
0.49
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.37
group Ids
OG000
OG003
non Inferiority Type
SUPERIORITY
param Type
Cox Proportional Hazard
param Value
0.82

Complete source fields

analyses

ci Lower Limit
0.67
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
2.10
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
param Type
Cox Proportional Hazard
param Value
1.19
ci Lower Limit
0.82
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
2.47
group Ids
OG000
OG002
non Inferiority Type
SUPERIORITY
param Type
Cox Proportional Hazard
param Value
1.43
ci Lower Limit
0.49
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.37
group Ids
OG000
OG003
non Inferiority Type
SUPERIORITY
param Type
Cox Proportional Hazard
param Value
0.82

classes

categories
measurements
group Id
OG000
value
22
group Id
OG001
value
26
group Id
OG002
value
30
group Id
OG003
value
24

denoms

counts
group Id
OG000
value
107
group Id
OG001
value
110
group Id
OG002
value
112
group Id
OG003
value
112
units
Participants

description

Number of Participants who Died Due to Any Cause

groups

description
Patients receive paclitaxel (pac) IV over 60 minutes once weekly in weeks 1-12. Patients then receive dose-dense doxorubicin hydrochloride IV over 5-10 minutes and cyclophosphamide IV over 5-30 minutes (ddAC) once in weeks 13, 15, 17, and 19. doxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV
id
OG000
title
Arm 1 (Pac --> ddAC)
description
Patients receive pac and ddAC as in arm 1. Patients also receive bevacizumab (bev) IV over 30-90 minutes in weeks 1, 3, 5, 7, 9, 11, 13, 15, and 17. doxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV bevacizumab: Given IV
id
OG001
title
Arm 2 (Pac + Bev --> ddAC + Bev)
description
Patients receive pac and ddAC as in arm 1. Patients also receive carboplatin IV over 30 minutes once in weeks 1, 4, 7, and 10. doxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV carboplatin: Given IV
id
OG002
title
Arm 3 (Pac + Carboplatin --> ddAC)
description
Patients receive pac and ddAC as in arm 1, bev as in arm 2, and carboplatin as in arm 3. doxorubicin hydrochloride: Given IV paclitaxel: Given IV cyclophosphamide: Given IV bevacizumab: Given IV carboplatin: Given IV
id
OG003
title
Arm 4 (Pac + Carboplatin + Bev --> ddAC + Bev)

param Type

COUNT_OF_PARTICIPANTS

population Description

All treated patients

reporting Status

POSTED

time Frame

up to 10 years

title

Overall Survival

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice